Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
-
J Dtsch Dermatol Ges · May 2012
ReviewCurrent advances and perspectives in the treatment of advanced melanoma.
Melanoma has long been considered as an extremely therapy-resistant tumour. Recent developments in the area of immunotherapy as well as targeted therapy showed rapid development and excellent results. ⋯ Another approval is expected in Europe for the specific BRAF-inhibitor vemurafenib, which has shown a significant impact on progression-free survival and overall survival in patients with the BRAF(V600E) mutation. In this review the relevant agents in the substance classes of immunomodulatory drugs and small molecules are presented and discussed, and future prospects for combination therapies and developments in melanoma treatment are outlined.